Exelixis Update on COVID-19
We continue to monitor the evolving Coronavirus Disease 2019 (COVID-19) pandemic and are adhering to guidance issued by health authorities. From the onset of this pandemic, we moved decisively to implement the applicable policies and procedures outlined in our robust business continuity program to ensure patients continue to receive the medicines they need and to protect the health and safety of our employees and contractors that provide onsite services at our organization.
Our Medicines and Clinical Trials
We do not expect there to be an impact on the availability of either of our commercial products (CABOMETYX® and COMETRIQ®) as we maintain a substantial amount of stock inventory throughout our broad and diverse supply chain.
We are actively monitoring our ongoing investigational studies at clinical trial sites across the globe and provide support to local investigators and patients participating in these trials to help minimize any potential impact on trial timelines.
Patients taking Exelixis medicines who have questions or concerns about their treatment plan should talk to their doctors. For any additional questions, please contact Exelixis Medical Information at email@example.com or 855-292-3935.
The health and safety of our staff members remains our top priority. We continue to follow the latest guidance issued by health authorities and have instituted several policies and procedures to protect against the spread of the disease which will remain in effect until further notice.
The statements in this notice relating to the availability of Exelixis’ commercial products, business plans and commitments are forward-looking statements that involve many risks and uncertainties. Our actual results could differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in Part II, Item 1A—“Risk Factors” included in the Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 5, 2020, and in Exelixis’ future filings with the SEC. All forward-looking statements in this notice are based on information available to Exelixis as of the date of this notice, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein.